SkinBioTherapeutics plc (AIM:SBTX)
London flag London · Delayed Price · Currency is GBP · Price in GBX
11.50
-0.75 (-6.12%)
Jul 24, 2026, 3:51 PM GMT

SkinBioTherapeutics Balance Sheet

Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Cash & Equivalents
3.124.780.81.311.84.61
Cash & Short-Term Investments
3.124.780.81.311.84.61
Cash Growth
-34.62%496.75%-38.95%-27.32%-60.85%113.51%
Accounts Receivable
0.760.760.40.190.140.27
Total Trade Receivables
0.760.760.40.190.140.27
Inventory
0.930.80.470.030.12-
Other Current Assets
---0.180.270.18
Total Current Assets
4.816.341.671.722.335.06
Net Property, Plant & Equipment
0.670.730.120.170.130.14
Other Intangible Assets
1.711.841.390.70.630.53
Goodwill
2.422.422.04---
Total Assets
9.611.335.222.593.085.73
Accounts Payable
0.651.280.50.50.480.38
Short-Term Debt
--0.74---
Current Portion of Leases
0.10.110.040.030.030.03
Other Current Liabilities
0.030.280.53---
Total Current Liabilities
0.781.681.80.530.510.4
Long-Term Debt
0.60.6----
Long-Term Leases
0.240.280.040.070.10.11
Other Long-Term Liabilities
--0.4---
Total Long-Term Liabilities
0.840.880.440.070.10.11
Total Liabilities
1.632.562.250.60.610.52
Common Stock
2.592.592.021.731.571.57
Additional Paid-in Capital
21.0921.0914.9511.398.768.76
Accumulated Other Comprehensive Income
0.440.44--0.440.38
Retained Earnings
-16.14-15.34-14-11.12-8.29-5.5
Shareholders' Equity
7.988.772.971.992.485.22
Total Liabilities & Equity
9.611.335.222.593.085.73
Total Debt
0.940.990.820.10.130.14
Net Cash (Debt)
2.193.79-0.021.211.684.47
Net Cash Growth
-42.27%---27.78%-62.48%107.04%
Net Cash Per Share
0.010.02-0.010.010.03
Book Value
7.988.772.971.992.485.22
Book Value Per Share
0.030.040.020.010.020.04
Tangible Book Value
3.854.51-0.461.291.854.69
Tangible Book Value Per Share
0.020.02-0.000.010.010.03